Synovics Pharmaceuticals, Inc. (SYVC)
- Previous Close
0.0001 - Open
0.0001 - Bid --
- Ask --
- Day's Range
0.0001 - 0.0001 - 52 Week Range
0.0001 - 0.0001 - Volume
200 - Avg. Volume
1,655 - Market Cap (intraday)
3,640 - Beta (5Y Monthly) 82.37
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Synovics Pharmaceuticals, Inc., through its subsidiaries, engages in the development, manufacture, and commercialization of generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products primarily in the United States. The company's OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives. It packages and distributes its products to chain drug stores, wholesalers, and distributors in the United States. The company was formerly known as Bionutrics Inc. and changed its name to Synovics Pharmaceuticals, Inc. in 2006. Synovics Pharmaceuticals, Inc. was founded in 1983 and is based in Fort Lauderdale, Florida. Synovics Pharmaceuticals, Inc. operates as a subsidiary of Maneesh Pharmaceuticals Limited.
155
Full Time Employees
October 31
Fiscal Year Ends
--
Sector
--
Industry
Related News
Performance Overview: SYVC
Trailing total returns as of 4/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SYVC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SYVC
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-26.42%
Return on Assets (ttm)
-12.75%
Return on Equity (ttm)
-314.28%
Revenue (ttm)
19.09M
Net Income Avi to Common (ttm)
-5.04M
Diluted EPS (ttm)
-0.1800
Balance Sheet and Cash Flow
Total Cash (mrq)
129.86k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.33M
Company Insights: SYVC
SYVC does not have Company Insights